Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Phibro Animal Health (PAHC)

Phibro completes $350 million acquisition of Zoetis medicated feed additive portfolio

Neutral Impact 4 of 5 m&a Written later

Phibro Animal Health completed its acquisition of Zoetis's medicated feed additive product portfolio and certain water-soluble products on October 31, 2024, for $350 million in cash, subject to adjustments. The company funded the purchase by borrowing $350 million under its July 3, 2024 Credit Agreement. The company expects the portfolio to boost profitability and EBITDA margin and to be accretive to Adjusted EPS, but the filing gives no specific figures and says more financial details will come at the Q1 earnings call on November 7.

Key points

  • Purchase price of $350 million in cash, subject to adjustments set out in the Purchase Agreement
  • Funded by $350 million of borrowings: $189 million of Delayed Draw Term A-1 Loans and $161 million of Delayed Draw Term A-2 Loans
  • Portfolio includes more than 37 product lines sold in about 80 countries, six manufacturing sites and more than 300 employees
  • Company expects accretion to Adjusted EPS; further financial details due on the Q1 earnings call on November 7

The filing

CompanyPhibro Animal Health (PAHC)
Form8-K, current report
Filed with the SECOct 31, 2024, 4:15 PM ET
Accession number0001104659-24-113064

Items reported: 2.01 Acquisition or Disposition Completed2.03 New Direct Financial Obligation7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:58 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 31, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.